Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial
- PMID: 17631211
- DOI: 10.1016/j.jacc.2007.03.038
Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial
Abstract
Objectives: The purpose of this study was to assess the association between B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and the incidence of specific cardiovascular events in low-risk patients with stable coronary disease, the incremental prognostic information obtained from these two biomarkers compared with traditional risk factors, and their ability to identify patients who may benefit from angiotensin-converting enzyme (ACE) inhibition.
Background: The prognostic value of BNPs in low-risk patients with stable coronary artery disease remains unclear.
Methods: Baseline plasma BNP and NT-proBNP concentrations were measured in 3,761 patients with stable coronary artery disease and preserved left ventricular function participating in the PEACE (Prevention of Events With Angiotensin-Converting Enzyme Inhibition) study, a placebo-controlled trial of trandolapril. Multivariable Cox regression was used to assess the association between natriuretic peptide concentrations and the incidence of cardiovascular mortality, fatal or nonfatal myocardial infarction, heart failure, and stroke.
Results: The BNP and NT-proBNP levels were strongly related to the incidence of cardiovascular mortality, heart failure, and stroke but not to myocardial infarction. In multivariable models, BNP remained associated with increased risk of heart failure, whereas NT-proBNP remained associated with increased risk of cardiovascular mortality, heart failure, and stroke. By C-statistic calculations, BNP and NT-proBNP significantly improved the predictive accuracy of the best available model for incident heart failure, and NT-proBNP also improved the model for cardiovascular death. The magnitude of effect of ACE inhibition on the likelihood of experiencing cardiovascular end points was similar, regardless of either BNP or NT-proBNP baseline concentrations.
Conclusions: In low-risk patients with stable coronary artery disease and preserved ventricular function, BNPs provide strong and incremental prognostic information to traditional risk factors.
Comment in
-
The use of B-type natriuretic peptides in coronary artery disease: utile or futile?J Am Coll Cardiol. 2007 Jul 17;50(3):215-6. doi: 10.1016/j.jacc.2007.04.035. Epub 2007 Jun 29. J Am Coll Cardiol. 2007. PMID: 17631212 No abstract available.
Similar articles
-
N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease.N Engl J Med. 2005 Feb 17;352(7):666-75. doi: 10.1056/NEJMoa042330. N Engl J Med. 2005. PMID: 15716560
-
Usefulness of combined high-sensitive C-reactive protein and N-terminal-probrain natriuretic peptide for predicting cardiovascular events in patients with suspected coronary artery disease.Coron Artery Dis. 2008 May;19(3):187-93. doi: 10.1097/MCA.0b013e3282f399e2. Coron Artery Dis. 2008. PMID: 18418236
-
Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study.Circulation. 2006 Jul 18;114(3):201-8. doi: 10.1161/CIRCULATIONAHA.105.590927. Epub 2006 Jul 10. Circulation. 2006. PMID: 16831981 Clinical Trial.
-
B-type natriuretic peptides: prognostic markers in stable coronary artery disease.Expert Rev Mol Diagn. 2008 Mar;8(2):217-25. doi: 10.1586/14737159.8.2.217. Expert Rev Mol Diagn. 2008. PMID: 18366308 Review.
-
Can measurement of B-type natriuretic peptide levels improve cardiovascular disease prevention?Clin Exp Pharmacol Physiol. 2008 Apr;35(4):442-6. doi: 10.1111/j.1440-1681.2008.04894.x. Clin Exp Pharmacol Physiol. 2008. PMID: 18307738 Review.
Cited by
-
Fatty acids and risk of dilated cardiomyopathy: A two-sample Mendelian randomization study.Front Nutr. 2023 Feb 16;10:1068050. doi: 10.3389/fnut.2023.1068050. eCollection 2023. Front Nutr. 2023. PMID: 36875854 Free PMC article.
-
Change in N-terminal-pro-B-type-natriuretic-peptide and the risk of sudden death, stroke, myocardial infarction, and all-cause mortality in diabetic dialysis patients.Eur Heart J. 2008 Sep;29(17):2092-9. doi: 10.1093/eurheartj/ehn278. Epub 2008 Jul 9. Eur Heart J. 2008. PMID: 18617483 Free PMC article. Clinical Trial.
-
B-type natriuretic peptide-guided therapy for perioperative medicine?Open Heart. 2014 Aug 5;1(1):e000105. doi: 10.1136/openhrt-2014-000105. eCollection 2014. Open Heart. 2014. PMID: 25332815 Free PMC article.
-
N-terminal pro-B-type natriuretic peptide and inducible ischemia in the Heart and Soul Study.Clin Cardiol. 2009 Aug;32(8):447-53. doi: 10.1002/clc.20569. Clin Cardiol. 2009. PMID: 19685518 Free PMC article.
-
Natriuretic peptides in heart failure: should therapy be guided by BNP levels?Nat Rev Cardiol. 2010 Jan;7(1):13-20. doi: 10.1038/nrcardio.2009.197. Epub 2009 Nov 24. Nat Rev Cardiol. 2010. PMID: 19935742 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous